Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor

Thrombosis Research

Volumn 101, Issue 3, 2001, Pages 145-157

  Elg, M ^a   Carlsson, S ^a   Gustafsson, D ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Activated prothrombin complex concentrate; Bleeding time; Feiba; Melagatran; NovoSeven; Rat; Thrombin inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ECARIN; HEMOGLOBIN; MELAGATRAN; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HEMOGLOBIN DETERMINATION; HEMOSTASIS; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOGENESIS;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BLEEDING TIME; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DRUG INTERACTIONS; FACTOR VII; GLYCINE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 0035251820     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00397-2     Document Type: Article

References (24)

1. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
2. The thrombin inhibitor melagatran and its prodrug H 376/95. Intestinal absorption properties and pharmacodynamic effects
3. Subcutaneous and oral direct thrombin inhibitors for prophylaxis of deep venous thrombosis and pulmonary embolism after total hip and knee replacement
4. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic low molecular weight thrombin inhibitor, in patients with acute deep vein thrombosis
5. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat
6. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary thrombolysis
7. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis
8. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor, in anaesthetised rats and rabbits
9. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
10. Amino acid sequence and posttranslation modifications of human factor VIIa from plasma and transfected baby hamster kidney cells
11. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
12. Multicenter restrospective study on the utilization of Feiba in France in patients with Factor VIII and Factor IX inhibitors
13. Recombinant factor VIIa in the treatment of internal bleeding in patients with factor VIII and IX inhibitors
14. Myocardial infarction after Feiba therapy in a hemophilia-B patient with a factor IX inhibitor
15. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor
16. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat
17. Effects of inogatran, a low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time
18. Determination of free haemoglobin in serum by an automated assay using 4-aminphenazone and the Cobas Bio System
19. Effect of recombinant F VIIa on warfarin-induced bleeding in rats
20. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CPG 39393) on bleeding in the rat
21. Assessment of bleeding for evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease
22. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study
23. Recombinant human factor VIIa (rF VIIa) in a rabbit stasis model
24. Factor VII and activated factor-VII content of prothrombin complex concentrates